PURR
NASDAQ · Biotechnology
Hyperliquid Strategies
$4.95
+0.07 (+1.43%)
Open$4.73
Previous Close$4.88
Day High$5.03
Day Low$4.65
52W High$6.63
52W Low$3.01
Volume—
Avg Volume7.22M
Market Cap626.24M
P/E Ratio—
EPS—
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+242.4% upside
Current
$4.95
$4.95
Target
$16.95
$16.95
$12.34
$16.95 avg
$26.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 243.91M | 233.99M | 197.33M |
| Net Income | 21.63M | 22.04M | 17.71M |
| Profit Margin | 8.9% | 9.4% | 9.0% |
| EBITDA | 48.94M | 46.22M | 40.39M |
| Free Cash Flow | 24.46M | 20.15M | 20.27M |
| Rev Growth | -3.3% | +11.1% | +4.4% |
| Debt/Equity | 0.58 | 0.61 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |